Blogs about: Exelixis
Featured Blog
GlaxoSmithKline chooses not to exercise right to MET/RET/VEGFR2 inhibitor XL184
GlaxoSmithKline has decided not to exercise its option to license MET/RET/VEGFR2 inhibitor from Exelixis… more →
Kinase News
Director's Chair
bioventuresforglobalhealth wrote 2 months ago: I am very pleased to let you know that Carl Feldbaum has been elected chairman of the BVGH Board of … more →
Keryx: Another beneficiary of the ASCO-effect
Michael Becker wrote 6 months ago: By Michael D. Becker In my prior article, I highlighted the “ASCO-effect,” which relates to the fact … more →
Exelixis and sanofi-aventis sign global license agreement
silico wrote 6 months ago: Sanofi-aventis and Exelixis Inc have announced a global license agreement for XL147 and XL765 and a … more →
Exelixis and Boehringer Ingelheim partners for autoimmune diseases
silico wrote 6 months ago: Exelixis and Boehringer Ingelheim have announced that they have established an exclusive, worldwide … more →
Boehringer Ingelheim partners with Exelixis
silico wrote 7 months ago: Exelixis and Boehringer Ingelheim have announced that they have established an exclusive, worldwide … more →
Your Science or Technology is on the Cutting Edge. Are Your People?
davidschull wrote 7 months ago: As The Leadership Edge writes on its Web site, great science or technology alone doesn’t make … more →
GlaxoSmithKline chooses not to exercise right to MET/RET/VEGFR2 inhibitor XL184
crimsoncanary wrote 1 year ago: GlaxoSmithKline has decided not to exercise its option to license MET/RET/VEGFR2 inhibitor from Exel … more →
Exelixis PI3K Inhibitor XL147 effective in Phase I
crimsoncanary wrote 1 year ago: Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K inhibitor XL147 to exhibit … more →
Exelixis PI3K/mTOR Inhibitor XL765 effective in Phase I
crimsoncanary wrote 1 year ago: Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K/mTOR kinase inhbitor XL765 … more →
Exelixis Raf kinase inhibitor XL281 effective in Phase I
crimsoncanary wrote 1 year ago: Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis RAF kinase inhbitor XL281 to sh … more →
Exelixis IGF-1R/Src inhibitor XL228 effective in Phase I
crimsoncanary wrote 1 year ago: Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis’ IGF-1R/Src inhibitor XL … more →
Exelixis MET/VEGFR2/RET inhibitor XL184 effective in Phase I
crimsoncanary wrote 1 year ago: Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis MET/VEGFR2/RET inhbitor XL184 d … more →
WO/2008/124161
kinasepro wrote 1 year ago: Exel’s got Pi3K-a in combination: Reminds one of the XL-147 combo study. So thats XL-647 ? I … more →
Exelixis Submit Due Diligence Report for Cdc7 Inhibitor XL413 to BMS
crimsoncanary wrote 1 year ago: Exelixis has submitted data to BMS on CDC7 inhibitor XL413. BMS has 30 days to decide whether it wan … more →
Exelixis MET/RET/VEGFR2 inhibitor XL184 achieves proof of concept in cancer
crimsoncanary wrote 1 year ago: Exelixis have announced that its MET/RET/VEGFR2 inhibitor XL184 has achieved proof of concept in hem … more →
Exelixis initiate Phase III trial of MET/RET/VEGFR2 inhibitor XL184 in Thyroid cancer
crimsoncanary wrote 1 year ago: Exelixis have initiated a phase III trial of MET/RET/VEGFR2 inhibitor XL184 for the treatment of med … more →
Exelixis and GlaxoSmithKline Conclude Six-Year Discovery and Development Collaboration
crimsoncanary wrote 1 year ago: Exelixis and GlaxoSmithKline will conclude their six-year collaboration in October 2008. GSK will ha … more →
Exelixis begin Phase II trial of multikinase inhibitor XL184 in Glioblastoma Multiforme
crimsoncanary wrote 1 year ago: Exelixis are initiating a Phase II trial of XL184 for the treatment of Malignant Glioma … more →
Exelixis begin Phase I trial of PI3K/mTOR inhibitor XL765 in Glioma
crimsoncanary wrote 1 year ago: Exelixis are initiating a Phase I trial of XL765, in combination with Temozolomide, for the treatmen … more →
